Hepatic steatosis in response to acute alcohol exposure in zebrafish requires sterol regulatory element binding protein activation

Michael J. Passeri, Ayca Cinaroglu, Chuan Gao, Kirsten C. Sadler – 28 January 2009 – Steatosis is the most common consequence of acute alcohol abuse and may predispose to more severe hepatic disease. Increased lipogenesis driven by the sterol response element binding protein (SREBP) transcription factors is essential for steatosis associated with chronic alcohol ingestion, but the mechanisms underlying steatosis following acute alcohol exposure are unknown.

Rat hepatocyte spheroids formed by rocked technique maintain differentiated hepatocyte gene expression and function

Colleen M. Brophy, Jennifer L. Luebke‐Wheeler, Bruce P. Amiot, Harris Khan, Rory P. Remmel, Piero Rinaldo, Scott L. Nyberg – 28 January 2009 – The culture of primary hepatocytes as spheroids creates an efficient three‐dimensional tissue construct for hepatic studies in vitro. Spheroids possess structural polarity and functional bile canaliculi with normal differentiated function. Thus, hepatocyte spheroids have been proposed as the cell source in a variety of diagnostic, discovery, and therapeutic applications, such as a bioartificial liver.

Reply:

George V. Papatheodoridis, Emanuel K. Manesis, Spilios Manolakopoulos, Ioannis S. Elefsiniotis, John Goulis, Athanasios J. Archimandritis – 28 January 2009

Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation

Eva U. Sotil, Jeanne Gottstein, Edgar Ayala, Christopher Randolph, Andres T. Blei – 28 January 2009 – In the current Model for End‐Stage Liver Disease allocation system, patients are at risk of suffering repeated episodes of hepatic encephalopathy (HE) while waiting for an orthotopic liver transplantation (OLT); the posttransplantation impact of these episodes has not been well explored.

Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard‐dose or reduced‐dose tacrolimus in liver transplant recipients

Björn Nashan, Faouzi Saliba, Francois Durand, Rafael Barcéna, Jose Ignacio Herrero, Gilles Mentha, Peter Neuhaus, Matthew Bowles, David Patch, Angel Bernardos, Jürgen Klempnauer, René Bouw, Jane Ives, Richard Mamelok, Diane McKay, Matt Truman, Paul Marotta – 28 January 2009 – The pharmacokinetics of mycophenolate mofetil (MMF) in liver transplant recipients may change because of pharmacokinetic interactions with coadministered immunosuppressants or because changes in the enterohepatic anatomy may affect biotransformation of MMF to mycophenolic acid (MPA) and enterohepatic recirculation of M

Subscribe to